To assess the potential impact of NLRP4 on the resistance of pancreatic cancer cells to olaparib, we administered varying doses of olaparib to NLRP4-knockdown or control stable BxPC-3 (BRCA wild type) and Capan-1 (possessing BRCA2 mutation) cell lines. Here, BRCA2 is linked to pancreatic neoplasm.